Publicaciones en colaboración con investigadores/as de University College London (15)

2024

  1. Psychopharmacology in children and adolescents: unmet needs and opportunities

    The Lancet Psychiatry, Vol. 11, Núm. 2, pp. 143-154

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  3. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications

    Neuroscience and Biobehavioral Reviews, Vol. 149

  4. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2021

  1. Pre-training inter-rater reliability of clinical instruments in an international psychosis research project

    Schizophrenia Research

  2. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  2. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

    Social Psychiatry and Psychiatric Epidemiology, Vol. 55, Núm. 5, pp. 645-657

2019

  1. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders

    Nature Communications, Vol. 10, Núm. 1

  2. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

    The Lancet Psychiatry, Vol. 6, Núm. 5, pp. 427-436

2018

  1. Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry, Vol. 75, Núm. 1, pp. 36-46

2016

  1. Autism spectrum disorder and schizophrenia: Boundaries and uncertainties

    BJ Psych Advances, Vol. 22, Núm. 5, pp. 316-324

2014

  1. Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations

    Schizophrenia Bulletin, Vol. 40, Núm. 4, pp. 729-736